Erica Acquarone

Erica Acquarone

Auto-generated profile, based on publicly available information

Erica Acquarone

Columbia University Irving Medical Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
EZElisa Zuccarello
Elisa Zuccarello
HZHong Zhang
Hong Zhang
EAErica Acquarone
Erica Acquarone
DPDang Pham
Dang Pham
ASAnna Staniszewski
Anna Staniszewski
JFJole Fiorito
Jole Fiorito

15 August 2025 in bioRxiv
Verified
Preprint
Open access
APAndrea Paquola
Andrea Paquola
EAErica Acquarone
Erica Acquarone
ASAgnieszka Staniszewski
Agnieszka Staniszewski
ATAndrew F. Teich
Andrew F. Teich
OAOttavio Arancio
Ottavio Arancio
Recent advances in sequencing have identified genetic risk factors for Alzheimer’s disease (AD), but the molecular mechanisms triggering disease onset remain unclear. While high brain levels of amyloid-beta (Aβ) impair synaptic function and memory, exposure to low picomolar (pM) Aβ concentrations - typical of healthy brains - enhances these functions, while sustained exposure results in impairment. To investigate this transition from physiological to pathological Aβ activity, we profiled DNA methylation and gene expression in C57B16 mice subjected to prolonged pM Aβ42 exposure. We identified differentially methylated and expressed genes, including those involved in synaptic function, associated with three phases: memory enhancement (brief exposure), a transitional state with intact memory (intermediate), and memory decline (prolonged). These gene sets may represent early molecular drivers of AD pathogenesis.

21 September 2025 in bioRxiv
Verified
Preprint
Open access
EAErica Acquarone
Erica Acquarone
SRSaktimayee Roy
Saktimayee Roy
ASAgnieszka Staniszewski
Agnieszka Staniszewski
DWD. Martin Watterson
D. Martin Watterson
OAOttavio Arancio
Ottavio Arancio
1. Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder and the leading cause of dementia worldwide. Progressive synaptic and neuronal loss underlies the decline in cognition and daily functioning, often accompanied by behavioral and psychological symptoms. Among these, neuropsychiatric disturbances such as agitation and aggression affect 20–65% of patients and represent a major source of caregiver burden. The serotonin receptor antagonist MW073 has recently emerged as a potential therapeutic candidate, showing efficacy in counteracting Aβ- and tau-induced synaptic and memory deficits in AD mouse models. Here, we investigated whether MW073 also mitigates aggressive behavior in Tg2576 mice, a widely used AD model that also displays heightened aggressiveness. Our findings demonstrate that MW073 significantly reduced aggressive tendencies in Tg2576 mice, suggesting that serotonergic modulation may represent a promising strategy to address both cognitive and neuropsychiatric symptoms of AD.

1 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
EAErica Acquarone
Erica Acquarone
SRSaktimayee Roy
Saktimayee Roy
ASAgnieszka Staniszewski
Agnieszka Staniszewski
DWD. Martin Watterson
D. Martin Watterson
OAOttavio Arancio
Ottavio Arancio
Background: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder and the leading cause of dementia worldwide. Progressive synaptic dysfunction underlies declines in cognition, daily functioning, and the development of neuropsychiatric syndromes. Neuropsychiatric syndromes that include agitation and aggression affect 40–60% of patients and represent a major source of caregiver burden. Serotonin 5-HT2B receptor levels are increased in the AD patient brain, and thus, treatment of AD animal models with the selective 5-HT2B receptor antagonist MW073 in prevention or disease stage paradigms attenuates Aβ- or tau-induced dysfunction. Methods: We investigated the effects of MW073 treatment on the aggressive behavior of Tg2576 mice in a resident–intruder assay. Results: MW073 treatment significantly reduced aggressive behavior in male Tg2576 mice. Conclusions: MW073 efficacy in treating aggression in Tg2576 mice implicates 5-HT2B receptor-mediated signaling in AD neuropsychiatric symptoms as well as cognitive and behavioral dysfunction.

28 October 2026 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
EAErica Acquarone
Erica Acquarone
SGSteve B. Garcia Gutierrez
Steve B. Garcia Gutierrez
HZHong Zhang
Hong Zhang
AMAlexander Morin
Alexander Morin
MMMaria Maccecchini
Maria Maccecchini
OAOttavio Arancio
Ottavio Arancio
INTRODUCTION: Alzheimer's disease (AD) results from disruptions in proteostasis, metabolism, and neurotrophic signaling that impair synaptic plasticity and memory. Dulaglutide, a blood–brain barrier (BBB)‐permeant glucagon‐like peptide‐1 (GLP‐1) receptor agonist, enhances phosphoinositide 3‐kinase (PI3K)/Akt and cAMP response element‐binding protein (CREB) signaling, while buntanetap reduces translation of aggregation‐prone proteins such as amyloid precursor protein (APP), tau, α‐synuclein, and transactive response DNA‐binding protein of 43 kDa. Although both compounds show cognitive benefits individually, their potential synergistic effects remain unexplored. METHODS: APP/presenilin 1 (PS1) mice and wild‐type (WT) littermates were treated with dulaglutide or buntanetap at high or subthreshold doses, alone or in combination, beginning at plaque deposition. Spatial memory was assessed through the 2‐day radial arm water maze (RAWM), associative memory using contextual fear conditioning, and hippocampal Schaffer collateral–CA1 long‐term potentiation (LTP) was evaluated as a measure of synaptic plasticity. Motor, sensory, motivational, and shock‐sensitivity controls were included to rule out confounding non‐cognitive effects. Meso Scale Discovery and Western blotting analyses were performed on frozen hippocampal tissue to assess amyloid beta (Aβ) and the postsynaptic density protein 95 (PSD95) marker levels. RESULTS: High doses of either dulaglutide or buntanetap alone rescued deficits in spatial and contextual memory as well as LTP in APP/PS1 mice, whereas lower doses produced minimal or partial benefit. Concurrent administration of low, individually ineffective doses of buntanetap (1 mg/kg) and dulaglutide (0.1 mg/kg) fully rescued RAWM performance, restored contextual fear memory and CA1 LTP, reduced Aβ levels, and restored PSD95. The combination treatment did not alter behavior in WT mice across control behavioral tasks, confirming treatment specificity for AD‐related deficits. DISCUSSION: Our findings demonstrate a strong synergistic interaction between BBB‐permeant dulaglutide and buntanetap at subthreshold doses, showing that combined enhancement of neurotrophic signaling and reduction of proteotoxic stress can rescue hippocampal dysfunction in early AD. This convergence between GLP‐1 receptor‐mediated pathways and inhibition of neurotoxic protein synthesis supports the clinical evaluation of GLP‐1‐based combination therapies with proteostatic modulators such as buntanetap.

14 July 2026 in Communications Biology
Verified
Journal Article
Open access
ACAna Paula Costa
Ana Paula Costa
EAErica Acquarone
Erica Acquarone
ALArtur Lazarian
Artur Lazarian
MHMathieu Herman
Mathieu Herman
KWKrista M. Wartchow
Krista M. Wartchow
LMLaura Beth McIntire
Laura Beth McIntire
Deficits in levels of phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] mediate Alzheimer's disease (AD) pathogenesis and etiology. The depletion of PI(4,5)P2 has been reported in AD in both human brain and animal models. Repletion of the synaptic pool of PI(4,5)P2, through haploinsufficiency of the degrading enzyme, Synaptojanin 1, ameliorated behavioral deficits in a mouse model of AD, in spite of accumulating amyloid. In order to refine the contribution of PI(4,5)P2 to AD, we used optogenetic translocation of the PI(4,5)P2-synthesizing enzyme, phosphoinositide phosphate 4 kinase2A (PIP4K2A) to the plasma membrane using light inducible dimerizable cryptochrome 2 (CRY-2) and the transcription factor CRY2-binding domain (CIBN) fused to the plasma membrane-targeting motif (CAAX). Spatiotemporally controlled production of phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] at the plasma membrane induced amelioration of behavioral deficits in a mouse model of AD. Imaging mass spectrometry confirmed alteration of specific PI(4,5)P2 acyl species, di-oleate, indicating that precise PI(4,5)P2 species may ultimately be leveraged for therapeutic intervention.